Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Interestingly, the likelihood of such events increased as vitamin D levels at the second study visit rose above 24 µg/dL in PD in the UMC/M model.

Source: Age is a strong determinant of CVDs, followed by Lp(a), troponin T, BMI and cholesterol. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

After one year, participants were re-evaluated to assess changes in laboratory findings, coronary artery status and plaque diameter following therapeutic intervention.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Cardiovascular risk assessment enhanced by automated machine learning in a multi-phase study

Study design awaiting verification · Scientific Reports · 2025

Original publication title

Cardiovascular risk assessment enhanced by automated machine learning in a multi-phase study

Igor Bibi; Daniel Schaffert; Philipp Blanke; Lorenz Illian; Federico Lenzing; Niklas Martin; Jan Leipe; Winfried März; Ksenija Stach; Victor Olsavszky

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and current predictors such as lipoprotein (a) [Lp(a)] and risk scores have limitations. Automated machine learning (AutoML) offers the potential to improve CVD risk prediction by processing large datasets and developing tailored models without the need for extensive data science expertise. Using clinical datasets from the LURIC (n = 3316) and UMC/M (n = 423) studies, we built AutoML models to predict Lp(a), specific CVDs and CVD-related mortality in three phases.

Phase 1 identified key CVD determinants such as age, Lp(a), troponin T, BMI and cholesterol with good accuracy (AUC 0.6249 to 0.9101). Phase 2 validated models in the UMC/M dataset and showed robust performance (AUC 0.7224 to 0.8417), with SHAP analysis highlighting predictors like statin therapy, age and NTproBNP. Phase 3 focused on cardiovascular mortality prediction, achieving high AUC values (0.74 to 0.85) and showed data drift, highlighting the need for model adjustment.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-24189-z.

Authors’ abstract

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and current predictors such as lipoprotein (a) [Lp(a)] and risk scores have limitations. Automated machine learning (AutoML) offers the potential to improve CVD risk prediction by processing large datasets and developing tailored models without the need for extensive data science expertise. Using clinical datasets from the LURIC (n = 3316) and UMC/M (n = 423) studies, we built AutoML models to predict Lp(a), specific CVDs and CVD-related mortality in three phases.

Phase 1 identified key CVD determinants such as age, Lp(a), troponin T, BMI and cholesterol with good accuracy (AUC 0.6249 to 0.9101). Phase 2 validated models in the UMC/M dataset and showed robust performance (AUC 0.7224 to 0.8417), with SHAP analysis highlighting predictors like statin therapy, age and NTproBNP. Phase 3 focused on cardiovascular mortality prediction, achieving high AUC values (0.74 to 0.85) and showed data drift, highlighting the need for model adjustment.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-24189-z.

Publication and source details

Original title: Cardiovascular risk assessment enhanced by automated machine learning in a multi-phase study

Igor Bibi; Daniel Schaffert; Philipp Blanke; Lorenz Illian; Federico Lenzing; Niklas Martin; Jan Leipe; Winfried März; Ksenija Stach; Victor Olsavszky

Scientific Reports · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Medizinische Fakultät Mannheim der Universität Heidelberg (8990)

Open Access funding enabled and organized by Projekt DEAL.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:07:47.744128+00:00

DOI: 10.1038/s41598-025-24189-z · PMC12537956